- Conditions
- Subjects Treated With Busulfan
- Interventions
- MyCare Oncology Busulfan Assay Kit
- Diagnostic Test
- Lead sponsor
- Saladax Biomedical, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • New Brunswick, New Jersey • Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 3,601
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Multiple Myeloma
- Interventions
- Total Skeletal Irradiation
- Radiation
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Multiple Myeloma
- Interventions
- Safety and efficacy assessments
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 9
- States / cities
- Palo Alto, California • Bethesda, Maryland • Boston, Massachusetts + 4 more
- Conditions
- Myeloma, Plasma-Cell, Lymphoma, Malignant, Myeloproliferative Disorders, Myelodysplastic Syndromes, Waldenstrom's Macroglobulinemia
- Interventions
- Reduced intensity conditioning with allogeneic transplant
- Procedure
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2007
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Multiple Myeloma
- Interventions
- No Intervention
- Other
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4,253 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 43
- States / cities
- Little Rock, Arkansas • La Jolla, California • Santa Rosa, California + 39 more
- Conditions
- Multiple Myeloma
- Interventions
- Bortezomib, Dexamethasone, PD 0332991
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 16
- States / cities
- Chicago, Illinois • Kansas City, Kansas • Westwood, Kansas + 9 more
- Conditions
- AL Amyloidosis
- Interventions
- daratumumab
- Drug
- Lead sponsor
- Boston Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Multiple Myeloma
- Interventions
- A (Thalidomide + Dexamethasone), B (Placebo + Dexamethasone)
- Drug
- Lead sponsor
- Celgene Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 470 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2013
- U.S. locations
- 26
- States / cities
- Hoover, Alabama • Tucson, Arizona • Los Angeles, California + 20 more
- Conditions
- Diffuse Large B Cell Lymphoma, Multiple Myeloma
- Interventions
- PointCheck
- Diagnostic Test
- Lead sponsor
- Leuko Labs, Inc.
- Industry
- Eligibility
- 10 Years and older
- Enrollment
- 210 participants
- Timeline
- 2025 – 2027
- U.S. locations
- 5
- States / cities
- Honolulu, Hawaii • Louisville, Kentucky • Boston, Massachusetts + 2 more
- Conditions
- Multiple Myeloma and Plasma Cell Neoplasm
- Interventions
- bortezomib
- Drug
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2012
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Relapsed Multiple Myeloma, Refractory Multiple Myeloma
- Interventions
- Nivolumab, Ixazomib, Dexamethasone, Cyclophosphamide
- Drug
- Lead sponsor
- Andrew Yee, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Danvers, Massachusetts
- Conditions
- Sickle Cell Disease (SCD)
- Interventions
- Not listed
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 10 Years to 85 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Myeloma
- Interventions
- Placebo, Minocycline
- Other · Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 79 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2022
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Systemic Amyloidosis
- Interventions
- Injection of peptide p5+14 radiolabeled with iodine-124 (124I-AT-01)
- Drug
- Lead sponsor
- University of Tennessee Graduate School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Knoxville, Tennessee
- Conditions
- Male Infertility, Nonobstructive Azoospermia, Azoospermia
- Interventions
- Platelet rich plasma
- Biological
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Multiple Myeloma
- Interventions
- Vermurafenib
- Drug
- Lead sponsor
- University of Arkansas
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
- Conditions
- Multiple Myeloma
- Interventions
- Linvoseltamab
- Biological
- Lead sponsor
- Dickran Kazandjian, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Amorphous, Eosinophilic, and Acellular Deposit, Constipation, Diarrhea, Early Satiety, Gastrointestinal Hemorrhage, Hepatomegaly, Lymphadenopathy, Macroglossia, Nausea, Primary Systemic Amyloidosis, Purpura, Recurrent Primary Amyloidosis, Refractory Primary Amyloidosis
- Interventions
- Isatuximab, Laboratory Biomarker Analysis
- Biological · Other
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 345
- States / cities
- Anchorage, Alaska • Hot Springs, Arkansas • Burbank, California + 234 more
- Conditions
- Hematologic Malignancies
- Interventions
- Romiplostim
- Drug
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Multiple Myeloma, Refractory
- Interventions
- Pembrolizumab, Belantamab mafodotin, Dexamethasone
- Drug
- Lead sponsor
- Hackensack Meridian Health
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 3
- States / cities
- Washington D.C., District of Columbia • Hackensack, New Jersey • Neptune City, New Jersey
- Conditions
- Optic Neuritis, Myelitis, Myelitis, Transverse
- Interventions
- High-dose corticosteroids (HDCS), High-dose corticosteroids (HDCS) and PLEX
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 382 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 35
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Loma Linda, California + 27 more
- Conditions
- Multiple Myeloma and Plasma Cell Neoplasm
- Interventions
- lenalidomide, melphalan, prednisone
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2013
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
- Conditions
- Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
- Interventions
- carfilzomib, dexamethasone, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 3
- States / cities
- Duarte, California • Rochester, Minnesota • St Louis, Missouri
- Conditions
- Hematological Malignancies
- Interventions
- Full intensity, double umbilical cord, stem cell transplant, Flu/Bu4 conditioning regimen, Total Lymphoid Irradiation (TLI), Graft versus Host Disease prevention (GVHD prophylaxis), Mycophenolate Mofetil
- Procedure · Drug · Radiation
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- Up to 65 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan